A 36-week, single-arm, open-label study to evaluate the safety and tolerability of ferric citrate in children with hyperphosphatemia related to chronic kidney disease.
Primary Objective
To assess the safety and tolerability of ferric citrate in pediatric subjects with hyperphosphatemia related to chronic kidney disease (CKD).
Description
A single arm trial evaluating efficacy of ferric citrate over 36 weeks in pediatric patients with hyperphosphatemia related to CKD.
Details
Age
Child
Eligibility
12-17 years old, diagnosis of CKD
Locations
Childrens Hospital Colorado
Principal Investigator
Weiwen Shih
Study ID
Protocol Number: 23-0073
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers